Pliant Therapeutics, Inc. (PLRX) stock
PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.70−0.04 (-5.81%)
Close on Nov 13, 2026Market cap $43.16MP/E –Yield 0.00%
Pliant Therapeutics cash
Cash and short-term investments held at the end of each period.
Pliant Therapeutics's cash was $141.08M at Sep 30, 2026. For fiscal 2025 it was $190.94M, down 46.5% from the year before. The highest annual figure on record is $495.73M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $190.94M | -46.5% |
| FY2024 | Dec 31, 2024 | $357.21M | -27.9% |
| FY2023 | Dec 31, 2023 | $495.73M | +49.7% |
| FY2022 | Dec 31, 2022 | $331.19M | +65.1% |
| FY2021 | Dec 31, 2021 | $200.60M | -27.6% |
| FY2020 | Dec 31, 2020 | $276.89M | +169.4% |
| FY2019 | Dec 31, 2019 | $102.77M | +68.6% |
| FY2018 | Dec 31, 2018 | $60.95M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $141.08M | -42.0% |
| Q2 FY2026 | Jun 30, 2026 | $158.10M | -40.2% |
| Q1 FY2026 | Mar 31, 2026 | $170.89M | -44.4% |
| Q4 FY2025 | Dec 31, 2025 | $190.94M | -46.5% |
| Q3 FY2025 | Sep 30, 2025 | $243.28M | -40.1% |
| Q2 FY2025 | Jun 30, 2025 | $264.36M | -39.7% |
| Q1 FY2025 | Mar 31, 2025 | $307.13M | -36.5% |
| Q4 FY2024 | Dec 31, 2024 | $357.21M | -27.9% |
| Q3 FY2024 | Sep 30, 2024 | $406.00M | -22.5% |
| Q2 FY2024 | Jun 30, 2024 | $438.09M | -21.1% |
| Q1 FY2024 | Mar 31, 2024 | $483.87M | -16.2% |
| Q4 FY2023 | Dec 31, 2023 | $495.73M | +49.7% |
| Q3 FY2023 | Sep 30, 2023 | $523.61M | +45.4% |
| Q2 FY2023 | Jun 30, 2023 | $555.16M | +239.3% |
| Q1 FY2023 | Mar 31, 2023 | $577.31M | +223.8% |
| Q4 FY2022 | Dec 31, 2022 | $331.19M | +65.1% |
| Q3 FY2022 | Sep 30, 2022 | $360.24M | +63.0% |
| Q2 FY2022 | Jun 30, 2022 | $163.60M | -32.9% |
| Q1 FY2022 | Mar 31, 2022 | $178.28M | -32.5% |
| Q4 FY2021 | Dec 31, 2021 | $200.60M | -27.6% |
| Q3 FY2021 | Sep 30, 2021 | $221.04M | -24.8% |
| Q2 FY2021 | Jun 30, 2021 | $243.98M | -21.9% |
| Q1 FY2021 | Mar 31, 2021 | $264.10M | +133.0% |
| Q4 FY2020 | Dec 31, 2020 | $276.89M | +169.4% |
| Q3 FY2020 | Sep 30, 2020 | $294.00M | +2476.0% |
| Q2 FY2020 | Jun 30, 2020 | $312.47M | +2315.5% |
| Q1 FY2020 | Mar 31, 2020 | $113.37M | +86.0% |
| Q4 FY2019 | Dec 31, 2019 | $102.77M | – |
| Q3 FY2019 | Sep 30, 2019 | $11.41M | – |
| Q2 FY2019 | Jun 30, 2019 | $12.94M | – |
| Q4 FY2018 | Dec 31, 2018 | $60.95M | – |
See a number that looks wrong?